Free Newsletter
Teva to cut 315 in Irish plant wind-down
Half of Teva Pharmaceutical's workers at a Waterford, Ireland, plant are getting the axe. In the second plant-layoff announcement this week, the Israeli generics maker told workers that 315 jobs will go, via a mixture of voluntary buyouts and layoffs. The cuts will come within 12 months as Teva stops making drug tablets at the plant.
The plant won't close completely, however; the remaining workers will still turn out inhalers for Teva. And word is that the tablet production isn't going away. It's just being transferred out of Ireland to Hungary, RTÉ News reports.
Teva's job-cuts news comes on the heels of Sanofi-Aventis' announcement that it would shut down a plant in Kansas City, MO. About 370 jobs are on the line there. It's all part of pharma's ongoing efforts to cut costs and streamline production. With two megadeals nearing closure--Merck and Schering-Plough's merger, and Pfizer's buyout of Wyeth--more manufacturing cuts are sure to come.
- read the RTÉ news
- get more from Inside Ireland
Related Articles:
Teva sues over "staggering" auction-rate loss
Rumors: Teva sets its sights on Shire
FDA bars Teva vet drugs on compliance issues
Teva on the hunt for 'major' acquisition
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: